Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Precision BioSciences Inc. (DTIL) on Thursday reported a loss of $20.6 million in its first quarter. On a per-share basis, the Durham, North Carolina-based ...

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -413.95% and 99.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock ...

Analysts estimate that Precision BioSciences will report an earnings per share (EPS) of $-2.42. Precision BioSciences bulls ...

Precision BioSciences (NASDAQ:DTIL) is scheduled to announce Q1 earnings results on Thursday, May 15th, before market open. The consensus EPS Estimate is -$2.42 (-242.4% Y/Y) and the consensus Revenue ...

Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 4.0% of Precision ...

The firm must deprioritize a mitochondrial disease program in order to fast-track PBGENE-DMD to a Phase I study.

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

Detailed price information for Precision Biosciences Inc (DTIL-Q) from The Globe and Mail including charting and trades.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the ...